Varicose Veins (Symptomatic Tributaries)
Investigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for varicose veins. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for symptomatic varicose-tributary relief is investigational.
- Какие доказательства существуют?
- Tier C (investigational). Two small case series (Cherniack 2010 n=18; Vejara-Rivera 2018 n=30) report symptomatic relief of leg heaviness, aching, and inflammation. There are no randomized controlled trials. Leech therapy does NOT correct the underlying venous reflux — varices typically recur. Definitive treatment is endovenous ablation (EVLA, RFA) or foam sclerotherapy, supported by extensive RCT evidence.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the leg for 5 to 10 days
- Itching and irritation at bite sites for days to weeks
- Local skin infection or, rarely, Aeromonas infection
- Hyperpigmentation around bite sites (more common in lower-extremity venous skin)
- Allergic reaction to leech saliva (uncommon)
- Small permanent scars at bite sites
- Triggering of superficial thrombophlebitis if applied to inflamed varices
- Кому не следует это рассматривать
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with active superficial thrombophlebitis or DVT
- Patients with critical limb ischemia or arterial insufficiency (ABI <0.7)
- Patients with active venous ulceration at the proposed site
- О чём спросить врача
- Have I been evaluated by a vascular surgeon or phlebologist with duplex ultrasound?
- Am I a candidate for endovenous ablation (EVLA, RFA) or sclerotherapy — the definitive treatments?
- What evidence supports leech therapy for varicose-vein symptoms specifically?
- What is the realistic chance of benefit, and for how long?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Will graduated compression stockings be used alongside?
- What is the cost, and what does it commit me to?
- Когда срочно обратиться за медицинской помощью
- Sudden leg swelling, pain, redness, or warmth (possible DVT)
- Chest pain, shortness of breath, or coughing blood (possible pulmonary embolism — call 911)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Что это НЕ означает
- This is not FDA-cleared for varicose veins.
- Leech therapy does NOT correct the underlying venous reflux — it is symptomatic only.
- Small uncontrolled case series do not constitute evidence of long-term benefit.
- Mechanism rationale (local anti-inflammation) does NOT establish clinical efficacy.
- Leech therapy is not a substitute for evaluation by a vascular specialist.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- vascular
- ICD-10
- I83.10, I83.811, I83.819, I83.93
- Safety tier
- low
Evidence Summary
A single small prospective clinical study (Bapat et al. 1998, n=20) applied medicinal leeches around complicated varicose veins with ulceration and reported ulcer healing, reduced oedema and limb girth in about 95% of patients, and reduced hyperpigmentation in about 75%; the authors themselves called for confirmation by controlled trials. Importantly, this is symptomatic and adjunctive relief — the underlying venous reflux is not corrected, and varices typically recur. Definitive treatment of axial reflux requires endovenous ablation (EVLA, RFA) or foam sclerotherapy. Leech therapy is therefore positioned only as an interim, investigational option for patients awaiting definitive treatment or refusing intervention. Avoid leech placement directly over thrombosed varicosities.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Cherniack EP (2010), n=18
- Vejara-Rivera M et al. (2018), n=30
Detailed Trial Entries
1 trial indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active deep vein thrombosis (acute phase <2 weeks)
- Critical limb ischemia (ABI <0.4)
- Active superficial thrombophlebitis
Related Conditions
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label use with controlled trial evidence for symptomatic improvement in venous claudication, leg heaviness, and edema in CEAP C3-C5 stages.
Venous Leg Ulcer
Off-label adjunct to compression therapy with case-series evidence for accelerated healing in compression-resistant venous ulcers.
Post-Thrombotic Syndrome
Off-label use with case-series evidence for symptomatic relief of leg pain, heaviness, and ulceration in PTS following deep vein thrombosis.
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; mechanism via local vasodilation and rheologic improvement. No RCT evidence.